• CPP, a small chemical molecule, promotes angiogenesis in vivo in a critical limb ischemia mouse model, enhancing blood perfusion and capillary density.
• Low-dose CPP (1 mg/kg/day) effectively restores perfusion and capillary density without organ toxicity, while high-dose (10 mg/kg/day) shows safety but less pronounced efficacy.
• In diabetic db/db mice, CPP treatment reverses diabetes-induced capillary loss in skin and muscle, indicating efficacy under metabolically unfavorable conditions.
• CPP acts directly in situ, without prior in vitro differentiation, suggesting a promising therapeutic strategy for peripheral artery disease.